Former White House Coronavirus Task Force coordinator under Deborah Birx has been named as the CEO of a pharmaceutical company.
Armata Pharmaceuticals announced in a July press release that Birx would be the new Chief Executive Officer of the biotechnology company.
“On behalf of the Armata Board and leadership, I would like to welcome Dr. Birx to the team. As we continue to work to introduce novel phage therapeutics to combat serious bacterial infections, Deborah’s expertise in immunology and infectious diseases together with her proven leadership skills will serve us well. I look forward to her contributions as CEO and a member of our Board,” Robin C. Kramer, Chair of Armata’s Board of Directors, said.
The California-based pharmaceutical company said it is currently “developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.”
From The Blaze:
Birx said of her new CEO position, "I am thrilled to join Armata at this pivotal time in the Company's development. I'm impressed with the scientific platform's quality and the team's commitment to introducing innovative treatment options for patients suffering from serious bacterial infections. I am excited about the recent advances and see multiple opportunities to accelerate the Company's progress and drive value creation. The recent investment enables the advancement of AP‐PA02 and AP‐SA02 in Phase 2 clinical trials."
